These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 20473501)

  • 1. Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.
    Kolarz B; Majdan M; Dryglewska M; Darmochwal-Kolarz D
    Rheumatol Int; 2011 Nov; 31(11):1439-43. PubMed ID: 20473501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
    Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
    Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
    Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
    Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
    Pertsinidou E; Saevarsdottir S; Manivel VA; Klareskog L; Alfredsson L; Mathsson-Alm L; Hansson M; Cornillet M; Serre G; Holmdahl R; Skriner K; Jakobsson PJ; Westerlind H; Askling J; Rönnelid J
    Ann Rheum Dis; 2024 Feb; 83(3):277-287. PubMed ID: 38049984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
    Caramaschi P; Biasi D; Tonolli E; Pieropan S; Martinelli N; Carletto A; Volpe A; Bambara LM
    Rheumatol Int; 2005 Nov; 26(1):58-62. PubMed ID: 15726373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity.
    Arntz OJ; Pieters BCH; Thurlings RM; Wenink MH; van Lent PLEM; Koenders MI; van den Hoogen FHJ; van der Kraan PM; van de Loo FAJ
    Front Immunol; 2018; 9():2388. PubMed ID: 30420853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
    Martínez-Estupiñán L; Hernández-Flórez D; Janta I; Ovalles-Bonilla JG; Nieto JC; González-Fernández CM; Del Río T; Monteagudo I; López-Longo FJ; Naredo E; Valor L
    Clin Exp Rheumatol; 2018; 36(1):88-93. PubMed ID: 28850020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis.
    Kastbom A; Roos Ljungberg K; Ziegelasch M; Wetterö J; Skogh T; Martinsson K
    Clin Exp Immunol; 2018 Dec; 194(3):391-399. PubMed ID: 30136282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
    Ahmed MM; Mubashir E; Wolf RE; Hayat S; Hall V; Shi R; Berney SM
    South Med J; 2006 Nov; 99(11):1209-15. PubMed ID: 17195414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.
    da Mota LM; Dos Santos Neto LL; de Carvalho JF; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Rheumatol Int; 2012 Dec; 32(12):3807-12. PubMed ID: 22187055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study.
    Ursum J; Bos WH; van Dillen N; Dijkmans BA; van Schaardenburg D
    Arthritis Res Ther; 2010; 12(1):R8. PubMed ID: 20064278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
    Aletaha D; Alasti F; Smolen JS
    Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
    de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
    Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.
    Cantaert T; van Baarsen LG; Wijbrandts CA; Thurlings RM; van de Sande MG; Bos C; van der Pouw Kraan TC; Verweij CL; Tak PP; Baeten DL
    Rheumatology (Oxford); 2010 Jan; 49(1):156-66. PubMed ID: 19933783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
    Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
    Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen.
    Ma MH; Scott IC; Dahanayake C; Cope AP; Scott DL
    J Rheumatol; 2014 Jul; 41(7):1298-303. PubMed ID: 24931951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.